Latest Breaking News On - Dopavision gmb - Page 1 : comparemela.com

Dopavision Announces Topline Results in Clinical Trial of Targeted Photobiomodulation Approach for Progressive Myopia

Safe and Tolerable: MyopiaX-1 proof-of-concept clinical trial (NCT04967287) supports MyopiaX's excellent safety and tolerability profile with no untoward safety events. Novel Approach: Dopavision's

Novartis pharmaDopavision gmbIan flitcroftMark wuttkeAbabax healthBoehringer ingelheim venture fundGerman federal ministry of educationBusiness wireCoordinating investigatorWith myopiaxSeventure partnersGerman federal ministryExecutive officerIhr portfolio

Dopavision Reports Successful Completion of Enrollment for MyopiaX-1 Trial

- MyopiaX-1 trial to generate first clinical evidence with MyopiaX®,a novel therapeutic approach to manage myopia progression

City ofUnited kingdomComunidad autonoma de catalunaLudger wess ines regina buthNovartis pharmaDopavision gmbMakula netzhaut zentrum breyer kaymakMark wuttkeGerman federal ministry of educationCentre for eye research dublinJohannes gutenberg universityBoehringer ingelheim venture fundErasmus university medical centerUniversity eye hospitalUniversity of minhoTechnological university dublin

Dopavision Reports Successful Completion of Enrollment for

- MyopiaX-1 trial to generate first clinical evidence with MyopiaX®, a novel therapeutic approach to manage myopia progression- First data readout expected.

United kingdomCity ofComunidad autonoma de catalunaLudger wess ines regina buthMakula netzhaut zentrum breyer kaymakNovartis pharmaMark wuttkeDopavision gmbUniversity complutenseUniversity eye hospitalBoehringer ingelheim venture fundGerman federal ministry of educationJohannes gutenberg universityAbabax healthUniversity of minhoUniversity medical center

Dopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are Active

Dopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are Active
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomCzech republicJames loughmanNovartis pharmaIan flitcroftLudger wess ines regina buthMark wuttkeDopavision gmbBoehringer ingelheim venture fundCentre for eye research irelandGerman federal ministry of educationAbabax healthEuropean society of ophthalmologyCongress onTechnological university of dublinPrincipal investigator

Dopavision Appoints Mark S Wuttke, Ph D , as Chief Executive Officer

Dopavision Appoints Mark S Wuttke, Ph D , as Chief Executive Officer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesTemple universityLudger wess ines regina buthStefan zundelMark wuttkeMarks wuttkeRahmenprogramm gesundheitsforschungDopavision gmbNovartis pharmaHamed bahmaniOphthalmology development unitGerman federal ministry of educationBoehringer ingelheim venture fundPrincipal at asten biopharma advisorsCognia corporation